Home | Welcome to Contract Pharma   
Last Updated Sunday, September 21 2014
Print

Financial Report: Alkermes



Published April 30, 2014
Alkermes
 
1Q Revenues: $130.2 million (-20%)
 
1Q Loss: $24.4 million (earnings were $3.0 million in 1Q13)
 
Comments: Manufacturing and royalty revenues were $111.3 in the quarter, down 24%, with AMPYRA/FAMPYRA down 17% to $20.6 million. Manufacturing and royalty revenues from the company’s antipsychotic franchise, RISPERDAL CONSTA and INVEGA SUSTENNA/XEPLION, were $49.6 million, up 9%. VIVITROL sales were $17.1 million, up 17%. Royalty revenue from BYDUREON was $7.7 million, up 60%. R&D expenses were $52.1 million, up 46% reflecting increased investment in the company’s CNS pipeline.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On